Kobo Biotech Ltd (531541)
Latest quarterly results (Q1 FY25)
In its latest reported quarter, Q1 FY25, Kobo Biotech's revenue was ₹0.0 Cr, and net profit ₹-1.3 Cr (a bigger loss than a year earlier).
| Q1 FY25 (₹ Cr) | Value | YoY vs Q1 FY24 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | — | — |
| Operating profit | ₹-0.3 | loss widened | loss widened |
| Net profit | ₹-1.3 | loss widened | loss widened |
| EPS (₹) | -0.56 | loss widened | loss widened |
📢 Recent Corporate Announcements
Kobo Biotech Ltd has reported a failure by the Successful Resolution Applicant (SRA), Beaufond Industries Limited, to implement the NCLT-approved resolution plan within the mandated timeline. The plan, approved by the NCLT Hyderabad Bench on May 11, 2026, required completion within 60 days, which expired on July 10, 2026. A Monitoring Committee meeting is being convened to decide the next course of action, creating significant uncertainty for the company's insolvency exit. The stock has seen a speculative 365.4% rise in the last 6 months despite these ongoing insolvency proceedings.
- NCLT Hyderabad Bench approved the Resolution Plan on May 11, 2026.
- Implementation deadline for the SRA was set for July 10, 2026 (60 days from approval).
- Successful Resolution Applicant (SRA) identified as Beaufond Industries Limited.
- Monitoring Committee meeting convened to deliberate on the failure to meet the deadline.
- Company remains under the supervision of an Insolvency Professional as of July 14, 2026.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
